Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7779140rdf:typepubmed:Citationlld:pubmed
pubmed-article:7779140lifeskim:mentionsumls-concept:C0014898lld:lifeskim
pubmed-article:7779140lifeskim:mentionsumls-concept:C0289799lld:lifeskim
pubmed-article:7779140lifeskim:mentionsumls-concept:C0023688lld:lifeskim
pubmed-article:7779140lifeskim:mentionsumls-concept:C0038477lld:lifeskim
pubmed-article:7779140lifeskim:mentionsumls-concept:C0449560lld:lifeskim
pubmed-article:7779140lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:7779140lifeskim:mentionsumls-concept:C0052313lld:lifeskim
pubmed-article:7779140pubmed:issue4lld:pubmed
pubmed-article:7779140pubmed:dateCreated1995-7-7lld:pubmed
pubmed-article:7779140pubmed:abstractTextThe pharmacological profiles of tertiary and quaternary monovalent (1b-6b) and bivalent ligands (7a-12b), closely related to arecaidine propargyl ester (CAS 35516-99-5, APE, 1a), were evaluated at muscarinic receptors in rat superior cervical ganglia (M1), rabbit was deferens (M1/M4-like), guinea-pig atria (M2) and guinea-pig ileum (M3). In the monovalent ligand series (1a-6b) APE (1a) displayed the highest potency at all three muscarinic receptors [M2 (-log EC50 = 8.12) > or = M3 (-log EC50 = 7.77) = M1/M4 (-log EC50/vas deferens = 7.72)], whereas in the bivalent ligand series (7a-12b) arecaidine 2-butyne-1,4-diyl bisester (bisABE, 7a) was the most potent agonist with functional selectivity for M1/M4 (-log EC50/vas deferens = 6.94) and M2 receptors (-log EC50 = 7.10) over M3 receptors (-log EC50 = 6.27). On ganglia bisABE elicited M2 receptor-mediated hyperpolarisations, which were followed by long-lasting pirenzepine-sensitive depolarisations. However, the potency at M1 receptors in ganglia of APE (-log EC50 = 6.96) and bisABE (-log EC50 = 5.69) was lower than that in rabbit vas deferens. All bivalent molecules exhibited decreased potencies when compared with their monovalent analogues. However, a change in potency profiles was often obtained. The quaternary isonicotinic acid 2-butyne-1,4-diyl bisester (10b) displayed some functional selectivity for M2 receptors (-log EC50 = 5.78) [6- to 9-fold over M1/M4 (-log EC50/vas deferens = 5.03) and M3 receptors (-log EC50 = 4.83)] without showing nicotinic effects.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:7779140pubmed:languageenglld:pubmed
pubmed-article:7779140pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7779140pubmed:citationSubsetIMlld:pubmed
pubmed-article:7779140pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7779140pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7779140pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7779140pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7779140pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7779140pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7779140pubmed:statusMEDLINElld:pubmed
pubmed-article:7779140pubmed:monthAprlld:pubmed
pubmed-article:7779140pubmed:issn0004-4172lld:pubmed
pubmed-article:7779140pubmed:authorpubmed-author:MoserUUlld:pubmed
pubmed-article:7779140pubmed:authorpubmed-author:GalvanMMlld:pubmed
pubmed-article:7779140pubmed:authorpubmed-author:LambrechtGGlld:pubmed
pubmed-article:7779140pubmed:authorpubmed-author:GubitzCClld:pubmed
pubmed-article:7779140pubmed:authorpubmed-author:Immel-SehrAAlld:pubmed
pubmed-article:7779140pubmed:authorpubmed-author:MutshclerEElld:pubmed
pubmed-article:7779140pubmed:issnTypePrintlld:pubmed
pubmed-article:7779140pubmed:volume45lld:pubmed
pubmed-article:7779140pubmed:ownerNLMlld:pubmed
pubmed-article:7779140pubmed:authorsCompleteYlld:pubmed
pubmed-article:7779140pubmed:pagination449-55lld:pubmed
pubmed-article:7779140pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7779140pubmed:meshHeadingpubmed-meshheading:7779140-...lld:pubmed
pubmed-article:7779140pubmed:meshHeadingpubmed-meshheading:7779140-...lld:pubmed
pubmed-article:7779140pubmed:meshHeadingpubmed-meshheading:7779140-...lld:pubmed
pubmed-article:7779140pubmed:meshHeadingpubmed-meshheading:7779140-...lld:pubmed
pubmed-article:7779140pubmed:meshHeadingpubmed-meshheading:7779140-...lld:pubmed
pubmed-article:7779140pubmed:meshHeadingpubmed-meshheading:7779140-...lld:pubmed
pubmed-article:7779140pubmed:meshHeadingpubmed-meshheading:7779140-...lld:pubmed
pubmed-article:7779140pubmed:meshHeadingpubmed-meshheading:7779140-...lld:pubmed
pubmed-article:7779140pubmed:meshHeadingpubmed-meshheading:7779140-...lld:pubmed
pubmed-article:7779140pubmed:meshHeadingpubmed-meshheading:7779140-...lld:pubmed
pubmed-article:7779140pubmed:meshHeadingpubmed-meshheading:7779140-...lld:pubmed
pubmed-article:7779140pubmed:meshHeadingpubmed-meshheading:7779140-...lld:pubmed
pubmed-article:7779140pubmed:meshHeadingpubmed-meshheading:7779140-...lld:pubmed
pubmed-article:7779140pubmed:year1995lld:pubmed
pubmed-article:7779140pubmed:articleTitleAliphatic and heterocyclic analogues of arecaidine propargyl ester. Structure-activity relationships of mono- and bivalent ligands at muscarinic M1 (M4), M2 and M3 receptor subtypes.lld:pubmed
pubmed-article:7779140pubmed:affiliationDepartment of Pharmacology, Biocentre Niederursel, University of Frankfurt, Germany.lld:pubmed
pubmed-article:7779140pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7779140pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:7779140pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed